Fermentalg has raised US$51 million
Fermentalg has raised US$51 million. US$16 million were raised from its existing shareholders, Demeter, Emertec, and ACE, and US$35 million from news investors, equity funds BPI France, IRDI, Viveris, and Sofiprotéol.
Fermentalg engages in the R&D and production of microalgae by heterotrophic pathway for health, algofuel and aquaculture.
Oaklins’ team in France advised Fermentlag in its fundraising.
Talk to the deal team
Related deals
CARSO Group has acquired a majority stake in AQCF Group
CARSO Group, a leading provider of testing services, has acquired a majority stake in AQCF Group, a key player in the field of food safety.
Learn morePrestige Inhome Care has found a long-term strategic partner
Prestige Inhome Care has received a growth capital investment from Yorkway Private. The newly formed partnership will provide growth capital for geographic expansion, increasing Prestige’s range of services and potential future acquisitions. The investment in Prestige is in line with Yorkway’s mandate to invest in leading Australian mid-market companies with strong management teams, backed by significant growth tail winds, as is the case in the aged care industry.
Learn moreCara Care has been acquired by Mahana Therapeutics
Mahana Therapeutics Inc., renowned for its pioneering digital treatments targeting chronic health issues, has recently finalized the acquisition of Cara Care (HiDoc Technologies GmbH). Cara Care stands out as a premier digital health platform and an official digital health application (DiGA) dedicated to enhancing gut health. This acquisition, supported by key investors Lux Capital and Jazz Ventures Partners, perfectly aligns with Mahana’s expansion strategy.
Learn more